Drug Profile

RT 102 - Regel Therapeutics

Alternative Names: RT-102 - Regel Therapeutics

Latest Information Update: 29 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Regel Therapeutics
Class Gene therapies
Mechanism of Action Gene expression modulators; NAV1.2 voltage-gated sodium channel expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

17 Sep 2025 Pharmacodynamics data from a preclinical study in CNS disorder released by Regel Therapeutics
17 Sep 2025 Preclinical trials in CNS disorders in USA (Parenteral) before September 2025 (Regel Therapeutics pipeline, September 2025)
02 Feb 2023 Early research in CNS disorders in USA (Parenteral) (Regel Therapeutics pipeline, February 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com